Market news

NOVATO, Calif., September 17, 2026--QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced the appointment of Mark L. Winkler, M.D., as Chief Medical Officer (CMO).

NOVATO, Calif., September 10, 2026--QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced its participation in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2026, taking place September 15–16, 2026. Chief Financial Officer Jay Jennings will deliver a company presentation at 3:30 pm ET on September 15, followed by o

QT Imaging Holdings Inc (QTI) reports record Q2 revenue of $7.4 million, driven by 15 scanner shipments, FDA clearance, and a new CPT code, despite wider net loss and margin pressure.

Motley Fool Press Release.

NOVATO, Calif., August 12, 2026--QT Imaging Holding, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and six months ended June 30, 2026, and provided a business update.

NOVATO, Calif., August 05, 2026--QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that it will report financial results for the second quarter ended June 30, 2026, after market close on Wednesday, August 12, 2026, and will host a conference call beginning at 4:30 p.m. Eastern Time. Participants are encouraged to pre-register at

NOVATO, Calif., August 04, 2026--QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today advanced the direct U.S. commercial strategy for its Breast Acoustic CT™ Scanner with the appointment of Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West. Both executives joined QT Imaging in July 2026

NOVATO, Calif., July 29, 2026--QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced the appointment of Julia Albright, Ph.D., as Chief Science Officer ("CSO"), effective July 27, 2026.

NOVATO, Calif., July 28, 2026--QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that the Israeli Ministry of Health has granted registration for the Company's scanner, authorizing commercialization of the system in Israel through February 2, 2028. The approval is based on the Company's existing U.S. FDA clearance and applicable

NOVATO, Calif., July 28, 2026--QT Imaging Holdings, Inc. ("QT Imaging" or the "Company") (NASDAQ: QTI), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced today that at the Annual Meeting of Company’s stockholders (the "Annual Meeting") held on July 28, 2026, the Company’s stockholders voted to approve (i) the election of Professor Zeev Weiner and Bryan Timm as Class II directors to serve until the Company’

NOVATO, Calif., July 07, 2026--QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company engaged in the research, development, and commercialization of innovative body imaging systems, announces the successful completion of its first routine inspection by the U.S. Food and Drug Administration (FDA), with zero Form 483 observations.